Incyclix Bio Announces $30 Million Series B Financing Led by Boxer Capital
Summary
Funds to support clinical development of INX-315, the companys lead Cyclin-Dependent Kinase 2 inhibitorSid Subramony, Ph.D., of Boxer Capital to join Incyclix Bios board of directorsRESEARCH TRIANGLE PARK, N.C., March 31, 2022 (GLOBE NEWSWIRE) -- Incyclix Bio, LLC (formerly Arc Therapeutics, LLC), a next-generation cell cycle control company, today announced the closing of a $30 million Series B financing led by new investor Boxer Capital. This financing will enable us to validate INX-315 in the clinic and generate proof of concept data to support future development.About Incyclix BioIncyclix Bio is a next-generation cell cycle control company advancing precision treatments that target the aberrant proliferation driving many cancers. Incyclix Bio is a scientific leader in understanding cyclin-dependent kinases (CDKs) and their role in the cell cycle as attractive therapeutic targets across many tumor types, including ovarian, breast and lung cancers. It was founded by Fred Eshelman, a highly regarded, successful entrepreneur with more than 40 years of executive, strategic, operational and financial leadership experience in the biopharmaceutical and healthcare industries. Previously, he founded and served as CEO and Executive Chairman of Pharmaceutical Product Development (PPDI, NASDAQ) prior to the sale of the company to private equity interests.